降钙素原清除率对重症肺炎患者临床结局的应用价值
该研究纳入2017年1月至2018年7月河北省涿州市医院ICU收治的58例年龄超过18岁的重症肺炎患者,根据治疗结局分为恢复组(33例,56.9%)和恶化组(25例,44.1%)。记录诊断后第1、3、5、7、9天血清降钙素原(PCT)水平并计算降钙素原清除率(PCTc),同时评估诊断24小时内APACHE II评分。恢复组与恶化组第1天和第3天PCT水平无显著差异,但第5、7、9天恢复组PCT显著低于恶化组(均P<0.01),且恢复组第3、5、7、9天PCTc均显著高于恶化组(均P<0.05)。ROC曲线分析显示第9天PCTc评估价值最大,AUC为0.978(95%CI=0.945-1.000,P=0.000),高于APACHE II(AUC=0.442,95%CI=0.280-0.610,P=0.392);最佳截断值93.00%时灵敏度99.0%、特异度87.3%。作者认为PCTc作为评估重症肺炎临床结局的指标具有良好应用价值。
要点
- 恢复组第9天PCTc中位数80.01%(59.86, 88.27)% vs 恶化组-38.15%(-99.38, -2.81)%,恢复组显著高于恶化组(P<0.05)。
- 第9天PCTc评估临床结局的AUC为0.978(95%CI=0.945-1.000,P=0.000),最佳截断值93.00%时灵敏度99.0%、特异度87.3%。
- 第9天PCTc的AUC(0.978)高于APACHE II评分(AUC=0.442,95%CI=0.280-0.610,P=0.392)。
- 恢复组第5、7、9天PCT显著低于恶化组(均P<0.01),而第1天和第3天两组PCT无显著差异(均P>0.05)。
- 恢复组第3、5、7、9天PCTc均显著高于恶化组(均P<0.05),随治疗时间延长恢复组PCT逐渐下降而恶化组维持较高水平。
适用人群与场景
- 年龄超过18岁、入住ICU的重症肺炎患者,来自河北省涿州市医院2017年1月至2018年7月收治的58例患者。
- 按治疗结局分为恢复组(肺炎症状体征消失或好转、X线胸片好转或无明显进展,33例)和恶化组(肺炎症状体征持续或进展、X线胸片进展,以及因肺部感染恶化累及其他器官功能或脓毒性休克等严重并发症,25例)。
诊断标准与关键阈值
- PCTc计算基于诊断重症肺炎后第1、3、5、7、9天血清PCT水平。
- 第9天PCTc评估临床结局的最佳截断值为93.00%,对应灵敏度99.0%、特异度87.3%。
研究设计与关键结果
- 研究类型为单中心队列研究,纳入58例重症肺炎患者,恢复组33例(56.9%)、恶化组25例(44.1%)。
- 第1天PCT恢复组5.05(3.89, 7.61)μg/L vs 恶化组5.29(4.15, 7.46)μg/L,第3天恢复组4.59(4.02, 6.90)μg/L vs 恶化组5.70(4.59, 7.28)μg/L,两组均P>0.05。
- 第5天PCT恢复组2.92(2.09, 3.42)μg/L vs 恶化组6.09(3.24, 7.96)μg/L,第7天恢复组1.94(1.50, 2.07)μg/L vs 恶化组7.65(5.60, 10.52)μg/L,第9天恢复组1.37(0.91, 1.74)μg/L vs 恶化组8.96(6.09, 10.87)μg/L,均P<0.01。
- 第3天PCTc恢复组15.10%(-17.80, 32.10)% vs 恶化组-1.53%(-20.80, 11.48)%,第5天恢复组47.50%(30.25, 60.34)% vs 恶化组6.25%(-14.58, 29.05)%,第7天恢复组76.44%(53.18, 77.92)% vs 恶化组-11.20%(-66.75, -1.38)%,第9天恢复组80.01%(59.86, 88.27)% vs 恶化组-38.15%(-99.38, -2.81)%,均P<0.05。
- ROC曲线分析显示第3、5、7、9天PCTc对评估临床结局均有价值,第9天PCTc价值最大,AUC=0.978(95%CI=0.945-1.000,P=0.000),高于APACHE II评分AUC=0.442(95%CI=0.280-0.610,P=0.392)。
证据类型、等级与局限
- 证据类型:单中心队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为PCTc作为评估重症肺炎临床结局的指标具有良好应用价值。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To investigate the changes in serum procalcitonin (PCT) in patients with severe pneumonia, and to analyze its value on evaluating the clinical outcome of patients with severe pneumonia.
METHODS: A total of 58 patients with severe pneumonia aged over 18 years, and admitted to intensive care unit (ICU) of Zhuozhou City Hospital of Hebei Province from January 2017 to July 2018 were enrolled. The patients were divided into recovery group (the symptoms and signs of pneumonia disappeared or improved, and the X-ray chest films improved or did not make significant progress) and deterioration group (the symptoms and signs of pneumonia persisted or progressed, while X-ray chest radiography progressed, as well as serious complications such as involvement of other organ functions due to deterioration of pulmonary infection or septic shock) according to the therapeutic outcome. The serum PCT levels at 1, 3, 5, 7, 9 days after severe pneumonia diagnosed were recorded, and procalcitonin clearance rate (PCTc) was calculated. The acute physiology and chronic health evaluation II (APACHE II) score was estimated within 24 hours when severe pneumonia was diagnosed. Receiver operating characteristic (ROC) curve was drawn, and the area under ROC curve (AUC) was calculated to analyze the value of PCTc on evaluating the clinical outcome of patients with severe pneumonia.
RESULTS: Among 58 patients, 33 (56.9%) had better outcome after active treatment (recovery group), and 25 (44.1%) had worse condition (deterioration group). There was no significant difference in PCT level at 1 day or 3 days between the recovery group and the deterioration group [μg/L: 5.05 (3.89, 7.61) vs. 5.29 (4.15, 7.46) at 1 day, 4.59 (4.02, 6.90) vs. 5.70 (4.59, 7.28) at 3 days, both P > 0.05]. With the prolongation of treatment time, serum PCT level was gradually decreased in the recovery group, while remained at higher level in the deterioration group, which was significantly lowered at 5, 7, 9 days in the recovery group as compared with that in the deterioration group [μg/L: 2.92 (2.09, 3.42) vs. 6.09 (3.24, 7.96) at 5 days, 1.94 (1.50, 2.07) vs. 7.65 (5.60, 10.52) at 7 days, 1.37 (0.91, 1.74) vs. 8.96 (6.09, 10.87) at 9 days, all P < 0.01]. PCTc at 3, 5, 7, 9 days in the recovery group were significantly higher than those in the deterioration group [15.10 (-17.80, 32.10)% vs. -1.53 (-20.80, 11.48)% at 3 days, 47.50 (30.25, 60.34)% vs. 6.25 (-14.58, 29.05)% at 5 days, 76.44 (53.18, 77.92)% vs. -11.20 (-66.75, -1.38)% at 7 days, 80.01 (59.86, 88.27)% vs. -38.15 (-99.38, -2.81)% at 9 days, all P < 0.05]. ROC curve analysis showed that PCTc at 3, 5, 7 and 9 days were valuable for evaluating the clinical outcome of patients with severe pneumonia, and 9-day PCTc had the greatest value, the AUC was 0.978 [95% confidence interval (95%CI) = 0.945-1.000, P = 0.000], which was higher than APACHE II (AUC = 0.442, 95%CI = 0.280-0.610, P = 0.392); when the best cut-off value of 9-day PCTc was 93.00%, its sensitivity was 99.0%, and specificity was 87.3%.
CONCLUSIONS: The PCT level of patients with severe pneumonia remained at a high level, which was related with the deterioration of the disease. PCTc, as an index to evaluate the clinical outcome of patients with severe pneumonia, has good application value.
参考来源
- Zheng G, Zhang J, Yuan Y, et al. [Application value of procalcitonin clearance rate on clinical outcome in patients with severe pneumonia]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2019. PMID: 31198141. doi:10.3760/cma.j.issn.2095-4352.2019.05.009
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。